Company continues to focus on upcoming results from ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients, expected in 2Q 2025In parallel, the ...

Chronic rhinosinusitis with nasal polyps presents a substantial clinical burden, affecting nasal airflow, olfactory function, ...

Research and development expenses were $21.8 million for the quarter ended December 31, 2024, compared to $11.6 million for the same period in 2023. The increase of $10.2 million was primarily driven ...

My husband has had an awful runny rose for several months. Our GP prescribed Beconase, but that hasn't worked. What advice do you have? Dr Ellie ...

A sinus infection, known as sinusitis, is one of the most common medical conditions. But in some cases, it can come with dangerous complications.

Medically reviewed by Jurairat J. Molina, MD Chronic rhinosinusitis is inflammation of the sinuses and nasal passages that ...

Positive results from the Tezspire phase III WAYPOINT trial highlight rapid and sustained effect in chronic rhinosinusitis with nasal polyps: Cambridge, UK Tuesday, March 4, 2025, ...

which could cause a potentially life-threatening infection, according to the U.S. Food and Drug Administration. Use of any SinuCleanse Soft Tip Squeeze Bottle Nasal Wash System products ...

Phase 3 trials showed significant improvements in nasal polyp size and obstruction. Our government trade tracker caught Pelosi’s 169% AI winner. Discover how to track all 535 Congress member ...

Secondary endpoint analyses from the trials showed 'significant improvements' in patients treated with the antibody.

Mepolizumab is associated with significantly improved outcomes in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) with previous nasal polyps (NP) surgeries, according to research ...

(RTTNews) - The Phase III WAYPOINT trial results revealed that AstraZeneca (AZN.L, AZN) and Amgen's (AMGN) TEZSPIRE (tezepelumab-ekko) significantly decreased nasal polyp severity, reduced the ...